Use antivenomics to map and license cross-neutralization of existing products against orphan species

The proposal

Apply antivenomics (proteomic antibody-binding profiling) plus preclinical neutralization assays to build a coverage map: for every medically important "orphan" species or regional population without a dedicated antivenom, identify existing polyvalent products whose antibodies already cross-neutralize it (paraspecificity), and pursue clinical validation and label extension so that product can be used there.

Why it would work

Antivenom antibodies bind conserved toxin structures, so a product raised against a few species often neutralizes untested relatives in the same genus or family. This paraspecific reach is frequently unmeasured, so effective coverage that already exists goes unused. Mapping it turns latent capacity into deployable treatment far faster and cheaper than developing new products.

Evidence

Assessments of the PANAF-Premium polyvalent antivenom found neutralizing potency against the venoms of 14 medically important snakes from 13 sub-Saharan African countries for which no specific product is marketed (PMC11050326). Similar paraspecific reach has been documented for anti-Bothrops, anti-Lachesis, and coral-snake antivenoms across Latin America, and for Thai polyvalent products against regional cobras and kraits.

Implementation path

Prioritize orphan species by burden; run antivenomics + murine neutralization panels against candidate polyvalent products; confirm the strongest matches in clinical studies; work with regulators to extend indications and with procurement bodies to redirect supply.

Trade-offs and limitations

In vitro binding and murine neutralization predict but do not guarantee clinical efficacy, so label extension still needs clinical confirmation. Cross-neutralization is often partial and weaker against geographically distant populations, so this extends coverage rather than guaranteeing it, and does not remove the need for genuinely broad-spectrum products.